These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Rhodanine derivatives as selective protease inhibitors against bacterial toxins. Johnson SL; Chen LH; Harbach R; Sabet M; Savinov A; Cotton NJ; Strongin A; Guiney D; Pellecchia M Chem Biol Drug Des; 2008 Feb; 71(2):131-9. PubMed ID: 18221310 [TBL] [Abstract][Full Text] [Related]
23. Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. Boldt GE; Kennedy JP; Hixon MS; McAllister LA; Barbieri JT; Tzipori S; Janda KD J Comb Chem; 2006; 8(4):513-21. PubMed ID: 16827563 [TBL] [Abstract][Full Text] [Related]
24. A High-Throughput Flow Cytometry Assay for Identification of Inhibitors of 3',5'-Cyclic Adenosine Monophosphate Efflux. Perez D; Simons PC; Smagley Y; Sklar LA; Chigaev A Methods Mol Biol; 2016; 1439():227-44. PubMed ID: 27316999 [TBL] [Abstract][Full Text] [Related]
25. Establishment and application of high throughput screening model for hepatitis C virus NS3-4A protease inhibitors in vitro. Jian-rui L; Yan-bin W; Shu-yi S; Hong-shan C; Jian-dong J; Zong-gen B Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):98-101. PubMed ID: 21375947 [TBL] [Abstract][Full Text] [Related]
26. Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening. Leroux F; Bosc D; Beghyn T; Hermant P; Warenghem S; Landry V; Pottiez V; Guillaume V; Charton J; Herledan A; Urata S; Liang W; Sheng L; Tang WJ; Deprez B; Deprez-Poulain R Eur J Med Chem; 2019 Oct; 179():557-566. PubMed ID: 31276900 [TBL] [Abstract][Full Text] [Related]
27. Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. Schmidt JJ; Stafford RG Appl Environ Microbiol; 2003 Jan; 69(1):297-303. PubMed ID: 12514008 [TBL] [Abstract][Full Text] [Related]
28. Computer-aided identification, synthesis, and biological evaluation of novel inhibitors for botulinum neurotoxin serotype A. Teng YH; Berger WT; Nesbitt NM; Kumar K; Balius TE; Rizzo RC; Tonge PJ; Ojima I; Swaminathan S Bioorg Med Chem; 2015 Sep; 23(17):5489-95. PubMed ID: 26275678 [TBL] [Abstract][Full Text] [Related]
29. Protocol for high-throughput compound screening using flow cytometry in THP-1 cells. Spangenberg SH; Zavareh RB; Lairson LL STAR Protoc; 2021 Jun; 2(2):100400. PubMed ID: 33778785 [TBL] [Abstract][Full Text] [Related]
30. High-throughput assays for botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F. Schmidt JJ; Stafford RG; Millard CB Anal Biochem; 2001 Sep; 296(1):130-7. PubMed ID: 11520041 [TBL] [Abstract][Full Text] [Related]
31. Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A. Roxas-Duncan V; Enyedy I; Montgomery VA; Eccard VS; Carrington MA; Lai H; Gul N; Yang DC; Smith LA Antimicrob Agents Chemother; 2009 Aug; 53(8):3478-86. PubMed ID: 19528275 [TBL] [Abstract][Full Text] [Related]
32. High-throughput identification of promiscuous inhibitors from screening libraries with the use of a thiol-containing fluorescent probe. McCallum MM; Nandhikonda P; Temmer JJ; Eyermann C; Simeonov A; Jadhav A; Yasgar A; Maloney D; Arnold AL J Biomol Screen; 2013 Jul; 18(6):705-13. PubMed ID: 23446699 [TBL] [Abstract][Full Text] [Related]
33. Toward the discovery of dual inhibitors for botulinum neurotoxin A: concomitant targeting of endocytosis and light chain protease activity. Seki H; Xue S; Hixon MS; Pellett S; Remes M; Johnson EA; Janda KD Chem Commun (Camb); 2015 Apr; 51(28):6226-9. PubMed ID: 25759983 [TBL] [Abstract][Full Text] [Related]
34. High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease. Balasubramanian A; Manzano M; Teramoto T; Pilankatta R; Padmanabhan R Antiviral Res; 2016 Oct; 134():6-16. PubMed ID: 27539384 [TBL] [Abstract][Full Text] [Related]
35. Fluorescence resonance energy transfer assay for high-throughput screening of ADAMTS1 inhibitors. Peng J; Gong L; Si K; Bai X; Du G Molecules; 2011 Dec; 16(12):10709-21. PubMed ID: 22186957 [TBL] [Abstract][Full Text] [Related]
36. High-throughput screening of improved protease inhibitors using a yeast cell surface display system and a yeast cell chip. Aoki W; Yoshino Y; Morisaka H; Tsunetomo K; Koyo H; Kamiya S; Kawata N; Kuroda K; Ueda M J Biosci Bioeng; 2011 Jan; 111(1):16-8. PubMed ID: 20832357 [TBL] [Abstract][Full Text] [Related]
37. Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease. Stowe GN; Silhár P; Hixon MS; Silvaggi NR; Allen KN; Moe ST; Jacobson AR; Barbieri JT; Janda KD Org Lett; 2010 Feb; 12(4):756-9. PubMed ID: 20092262 [TBL] [Abstract][Full Text] [Related]
38. Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. Boldt GE; Kennedy JP; Janda KD Org Lett; 2006 Apr; 8(8):1729-32. PubMed ID: 16597152 [TBL] [Abstract][Full Text] [Related]
39. Yeast-hybrid based high-throughput assay for identification of anthrax lethal factor inhibitors. Kim J; Park HC; Gedi V; Park HY; Roberts AG; Atkins WM; Yoon MY Biochem Biophys Res Commun; 2011 Jan; 404(1):517-22. PubMed ID: 21144836 [TBL] [Abstract][Full Text] [Related]
40. A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity. Schmidt JJ; Stafford RG FEBS Lett; 2002 Dec; 532(3):423-6. PubMed ID: 12482605 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]